Hologic Completes Acquisition of Mobidiag
June 17 2021 - 8:45AM
Business Wire
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health,
has completed its previously announced acquisition of Mobidiag Oy,
an innovator in near-patient, acute care molecular diagnostic
testing, for an enterprise value of approximately $808 million.
“Closing the acquisition of Mobidiag enables us to become a
broader, more diversified global diagnostics leader,” said Jan
Verstreken, group president, international at Hologic. “Together,
we can accelerate development and adoption of Mobidiag’s innovative
products globally and drive Hologic’s growth.”
Mobidiag provides near-patient, molecular diagnostic instruments
and tests for acute care conditions including gastrointestinal and
respiratory infections, antimicrobial resistance management, and
healthcare associated infections. Its Amplidiag and Novodiag
testing platforms deliver results in 50 minutes to two hours. The
Novodiag platform combines real-time PCR and microarray
capabilities to provide high-level multiplexing. Multiplexing
enables multiple pathogens to be identified in a single sample,
streamlining workflows for laboratories and providing rapid results
to physicians.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women's health and well-being
through early detection and treatment. For more information on
Hologic, visit www.hologic.com.
Hologic and The Science of Sure are trademarks and/or registered
trademarks of Hologic, Inc. and/or its subsidiaries in the United
States and/or other countries.
Forward-Looking
Statements
This news release contains forward-looking information that
involves risks and uncertainties, including statements about
Hologic’s plans, objectives, expectations and intentions. Such
statements include, without limitation: financial or other
information based upon or otherwise incorporating judgments or
estimates relating to future performance, events or expectations;
strategies, positioning, resources, capabilities, and expectations
for future performance; and financial outlook and other guidance.
These forward-looking statements are based upon assumptions made as
of this date and are subject to known and unknown risks and
uncertainties that could cause actual results to differ materially
from those anticipated.
Risks and uncertainties that could adversely affect Hologic’s
business and prospects, and otherwise cause actual results to
differ materially from those anticipated, include without
limitation: the possibility that the anticipated benefits from the
transaction cannot be fully realized or may take longer to realize
than expected; the possibility that costs or difficulties related
to the integration of Mobidiag’s operations with those of Hologic
will be greater than expected; the ability of Hologic and Mobidiag
to retain and hire key personnel; the coverage and reimbursement
decisions of third-party payers and the guidelines,
recommendations, and studies published by various organizations
relating to the use of products and treatments; the ability to
successfully manage ongoing organizational and strategic changes,
including Hologic's ability to attract, motivate and retain key
employees; the development of new competitive technologies and
products; regulatory approvals and clearances for products; the
anticipated development of markets in which products are sold into
and the success of products in these markets; the anticipated
performance and benefits of products; estimated asset and liability
values; anticipated trends relating to Hologic's financial
condition or results of operations; and Hologic's capital resources
and the adequacy thereof.
The risks included above are not exhaustive. Other factors that
could adversely affect Hologic’s business and prospects are
described in Hologic’s filings with the SEC. Hologic expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any such statements presented herein to
reflect any change in expectations or any change in events,
conditions or circumstances on which any such statements are
based.
Source: Hologic, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210617005517/en/
Media Contact Jane Mazur Vice President, Divisional
Communications (508) 263-8764
Investor Contact Michael Watts Vice President, Investor
Relations and Corporate Communications (858) 410-8588
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From Apr 2024 to May 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
From May 2023 to May 2024